CLEVIPREX's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11103490 | CHIESI | Clevidipine emulsion formulations containing antimicrobial agents |
Oct, 2031
(8 years from now) | |
| US10010537 | CHIESI | Clevidipine emulsion formulations containing antimicrobial agents |
Oct, 2031
(8 years from now) | |
| US8658676 | CHIESI | Clevidipine emulsion formulations containing antimicrobial agents |
Oct, 2031
(8 years from now) | |
Cleviprex is owned by Chiesi.
Cleviprex contains Clevidipine.
Cleviprex has a total of 3 drug patents out of which 0 drug patents have expired.
Cleviprex was authorised for market use on 01 August, 2008.
Cleviprex is available in emulsion;intravenous dosage forms.
The generics of Cleviprex are possible to be released after 10 October, 2031.
Drugs and Companies using CLEVIDIPINE ingredient
Market Authorisation Date: 01 August, 2008
Treatment: NA
Dosage: EMULSION;INTRAVENOUS
How can I launch a generic of CLEVIPREX before it's drug patent expiration?
More Information on Dosage
CLEVIPREX family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic